Cellebrite DI Ltd. (NASDAQ:CLBT - Get Free Report) CFO David Barter sold 12,134 shares of the company's stock in a transaction dated Friday, October 16th. The stock was sold at an average price of $11.21, for a total value of $136,022.14. Following the completion of the transaction, the chief financial officer owned 322,085 shares of the company's stock, valued at $3,610,572.85. The trade was a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Cellebrite DI Stock Performance
Shares of Cellebrite DI stock opened at $11.03 on Monday. The firm has a market capitalization of $2.75 billion, a PE ratio of 50.14, a price-to-earnings-growth ratio of 1.69 and a beta of 1.14. Cellebrite DI Ltd. has a 12 month low of $9.58 and a 12 month high of $19.98. The business's 50-day moving average price is $11.62 and its 200-day moving average price is $13.10.
Hedge Funds Weigh In On Cellebrite DI
A number of large investors have recently bought and sold shares of the stock. Nine Ten Capital Management LLC boosted its holdings in shares of Cellebrite DI by 19.8% during the 2nd quarter. Nine Ten Capital Management LLC now owns 4,126,808 shares of the company's stock valued at $60,251,000 after buying an additional 682,933 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Cellebrite DI by 93.7% in the 2nd quarter. Wellington Management Group LLP now owns 3,049,904 shares of the company's stock worth $44,529,000 after acquiring an additional 1,475,579 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Cellebrite DI by 14.7% in the 1st quarter. Renaissance Technologies LLC now owns 2,860,639 shares of the company's stock worth $39,420,000 after acquiring an additional 365,700 shares in the last quarter. Principal Financial Group Inc. lifted its position in Cellebrite DI by 33.9% during the 1st quarter. Principal Financial Group Inc. now owns 2,156,166 shares of the company's stock valued at $29,712,000 after acquiring an additional 545,334 shares during the period. Finally, Meitav Investment House Ltd. lifted its position in Cellebrite DI by 34.4% during the 1st quarter. Meitav Investment House Ltd. now owns 1,954,846 shares of the company's stock valued at $26,938,000 after acquiring an additional 500,000 shares during the period. 45.88% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of research analysts have commented on CLBT shares. Weiss Ratings cut shares of Cellebrite DI from a "sell (d+)" rating to a "sell (d)" rating in a research report on Thursday, August 27th. Lake Street Capital lowered their price objective on shares of Cellebrite DI from $21.00 to $15.00 and set a "buy" rating for the company in a report on Friday, August 14th. DA Davidson reaffirmed a "buy" rating and issued a $15.00 price objective on shares of Cellebrite DI in a research note on Tuesday, September 15th. JPMorgan Chase & Co. reduced their target price on shares of Cellebrite DI from $20.00 to $16.00 and set an "overweight" rating on the stock in a report on Friday, August 14th. Finally, Needham & Company LLC decreased their target price on shares of Cellebrite DI from $15.00 to $12.50 and set a "buy" rating on the stock in a research report on Friday, August 14th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $16.70.
Check Out Our Latest Analysis on Cellebrite DI
Cellebrite DI Company Profile
(
Get Free Report)
Cellebrite DI Ltd. is a digital intelligence company that develops technology for collecting, managing and analyzing digital evidence. Its solutions are designed to help law enforcement agencies, public safety organizations, government bodies and enterprises investigate activity involving mobile devices, computers, cloud services and other digital sources.
The company's product portfolio includes tools for mobile-device extraction and digital forensics, investigative analytics, evidence management and collaboration.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
